June 27th, 2017
The Forgotten $35 Billion U.S. Healthcare Problem
Each year, more than 23,000 people die in the United States as a direct result of bacterial...
June 16th, 2017
Congratulations to our first PhD student: Dr. Vincent Trebosc on the successful completion of his studies!
Congratulations Vincent !
June 15th, 2017
ETH Zürich Trailer ist da! Kurzfilm in 120 Sekunden
Der ETH Zürich bringt einen neuen Kurzfilm , der die ETH Zürich den Zuschauerinnen und Zuschauern...
June 8th, 2017
Reviving a Drug for Tuberculosis ?
A compound called SMARt-420 renders ethionamide-resistant strains of Mycobacterium tuberculosis fully...
Recent Media Feeds
- BioVersys Receives QIDP Designation from the U.S. FDA for the Development of BV100
- Press Release - BioVersys hires new CDO, Dr. Glenn Dale
- Eurostars Funds IMPACT2 Press Release
- Press Release - New CFO at BioVersys - Matthias Werder
- Dr. Gitzinger will be speaking at the UNCTAD/WHO event in Geneva, October 23rd, 2018 from 14:30-17:30 on Fostering investment in the development of new antibacterial treatments
- CARB-X welcomes UK Government and Bill & Melinda Gates Foundation as new partners
- BioVersys successfully closes Series A2 financing round
- World Antibiotic Awareness Week - November 13-19th, 2017
- October 20th, 2017; BioVersys and Marc Gitzinger were featured in the 3Sat news.
- BEAM Alliance fordert G20 Staaten zu mehr Unterstützung im Kampf gegen tödliche Superkeime auf
- Swiss biopharma BioVersys is collaborating with drug discovery and development CRO Aptuit on the discovery and development of new targets and drug candidates against Gram-negative bacteria, including drug-resistant strains. An existing BioVersys target will be included in the partnership.
- Press Release BEAM Alliance / Biocom AG
- Breaking through the Wall ... A Call for Concerted Action on AB Research and Development
- Fighting AMR efficiently
- Beam Alliance appoints Marc Gitzinger as VP on the Board of Directors
